News & Updates

Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024 byJairia Dela Cruz

In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.

Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024 byStephen Padilla

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.

Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024
AI improves physician accuracy in identifying prostate cancer extent
AI improves physician accuracy in identifying prostate cancer extent
16 Aug 2024